Last 14,300 KRW
Change Today -300.00 / -2.05%
Volume 92.8K
083790 On Other Exchanges
Symbol
Exchange
KOSDAQ
As of 1:12 AM 09/3/14 All times are local (Market data is delayed by at least 15 minutes).

crystalgenomics inc (083790) Snapshot

Open
14,500
Previous Close
14,600
Day High
14,550
Day Low
14,200
52 Week High
08/4/14 - 19,500
52 Week Low
12/18/13 - 8,750
Market Cap
294.9B
Average Volume 10 Days
143.3K
EPS TTM
-628.00
Shares Outstanding
20.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CRYSTALGENOMICS INC (083790)

Related News

No related news articles were found.

crystalgenomics inc (083790) Related Businessweek News

No Related Businessweek News Found

crystalgenomics inc (083790) Details

CrystalGenomics, Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs based on structural chemoproteomics. The company offers 3D structure determination services; and soluble, active, pure, and homogenous disease related proteins. Its lead development candidate is NSAID (CG100649), which is a tissue specific anti-inflammatory agent with cardiovascular, gastrointestinal, and renal safety profiles. NSAID (CG100649) has completed a Phase IIa clinical trial in Europe. The company’s other products under pipeline comprise CG400549 that is in Phase I clinical trial for the treatment of multi-drug resistance of staphylococcus app, as well as VISA and VRSA; CG200745, an anti-cancer agent that deactivates HDAC, an enzyme that catalyzes the histone deacetylation; and HIF Stablilizer that is in preclinical stage for the treatment of anemia, myocardial infarction, stroke, inflammation, and other related diseases. The company has drug discovery collaborations with AstraZeneca, Daiichi-Sankyo, SBI-Biotech, Carna Biosciences, Yuyu Pharma, AmorePacific, Hanmi Pharmaceuticals, and ProQuest Investments. CrystalGenomics, Inc. is based in Seongnam-si, Korea.

crystalgenomics inc (083790) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

crystalgenomics inc (083790) Key Developments

CrystalGenomics, Inc. Presents at HSBC 2nd Annual Asia Investor Forum ­ London, Jun-09-2014

CrystalGenomics, Inc. Presents at HSBC 2nd Annual Asia Investor Forum ­ London, Jun-09-2014 . Venue: The May Fair Hotel, London, United Kingdom.

CrystalGenomics, Inc., Annual General Meeting, Mar 28, 2014

CrystalGenomics, Inc., Annual General Meeting, Mar 28, 2014., at 09:00 Korea Standard Time. Location: Bundang-gu. Agenda: To approve of 2013 financial statements; to approve some changes in the Articles of Association; to approve appointment of directors; to approve appointment of Auditor; to approve of Directors remuneration; to approve grant of stock options for employees; to approve Board of Directors' resolution; and to consider other references concerning investment decisions.

CrystalGenomics, Inc. - Shareholder/Analyst Call

To discuss company status and future business development

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
083790:KS 14,300.00 KRW -300.00

083790 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Daiichi Sankyo Co Ltd ¥1,853 JPY -0.50
View Industry Companies
 

Industry Analysis

083790

Industry Average

Valuation 083790 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 58.6x
Price/Book 8.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 52.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CRYSTALGENOMICS INC, please visit www.cgxinc.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.